Published in Clinical Trials Week, November 8th, 2004
The data from the formal treatment phase of the study was published in the December 2003 issue of Archives of Neurology.
All participants from the original 36-week blinded and placebo-controlled portion of the phase II trial were offered the opportunity to continue the PBT-1 treatment on an open label basis for an additional 48 weeks. 18 (66.7%) out of 27 patients elected to start the CQADEX extension study. Nine patients...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.